Collaborative research initiative for tumor profiling
A recent collaboration aims to improve understanding of cancer, by utilizing Protea’s molecular profiling MS technology.
Protea Biosciences Group Inc. (WV, USA) has recently announced a collaboration with the Memorial Sloan-Kettering Cancer Center (NY, USA) and the Dana-Farber Cancer Institute (MA, USA). The joint research initiative will utilize Protea’s laser ablation electrospray ionization (LAESI) direct molecular imaging technology to analyze cancer cells, initially focusing on early-stage lung adenocarcinoma.
The LAESI technology, which is used alongside MS, will enable the generation of molecular data profiles of cancer cells in biological samples; the researchers hope that this method will increase understanding of the cancer’s origin.
Chief Executive Officer of Protea, Steve Turner, commented, “We are pleased to have this opportunity to apply our LAESI technology to provide improved molecular profiling of cancer cells and tissue samples. In the future we anticipate applying our direct molecular profiling technology to other tissue sample types, including 3D cell cultures and synthetic biology tissues, to provide comprehensive molecular profiling of tumors rapidly and directly.”
